Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon Laboratories's Accounts Payable for the quarter that ended in Mar. 2026 was ₨3,175 Mil.
Highnoon Laboratories's quarterly Accounts Payable
declined
from Sep. 2025 (₨3,718 Mil) to Dec. 2025 (₨1,974 Mil) but then
increased
from Dec. 2025 (₨1,974 Mil) to Mar. 2026 (₨3,175 Mil).
Highnoon Laboratories's annual Accounts Payable
increased
from Dec. 2023 (₨909 Mil) to Dec. 2024 (₨1,815 Mil) and
increased
from Dec. 2024 (₨1,815 Mil) to Dec. 2025 (₨1,974 Mil).
Highnoon Laboratories Accounts Payable Related Terms
Highnoon Laboratories Accounts Payable Historical Data
* Premium members only.
The historical data trend for Highnoon Laboratories's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Highnoon Laboratories (KAR:HINOON) has a Accounts Payable of ₨3,175 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Highnoon Laboratories and its competitors.
Is Highnoon Laboratories' Accounts Payable too high?
Highnoon Laboratories' current Accounts Payable is ₨3,175 Mil. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' Accounts Payable compare to LLY and JNJ?
Highnoon Laboratories' Accounts Payable of ₨3,175 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Highnoon Laboratories and its competitors. Highnoon Laboratories's current Accounts Payable is ₨3,175 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,030.52, compared to a current price of ₨1,003.54 — trading 2.6% below its estimated fair value. The current Accounts Payable is ₨3,175 Mil. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current Accounts Payable is ₨3,175 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨1,003.54 is trading 2.6% below its estimated GF Value™ of ₨1,030.52.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
Accounts Payable: ₨3,175 Mil
GF Value™: ₨1,030.52 vs. price of ₨1,003.54 (2.6% below fair value)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
